Abstract 1279: Development of a selective CDK2-E inhibitor in CCNE driven cancers
Yoon Jong Choi(Blueprint Medicines (United States)), Marion Dorsch(Biogen (United States)), Riadh Lobbardi(Massachusetts General Hospital), Klaus P. Hoeflich(Pivot), Faith Stevison(Blueprint Medicines (United States)), Doug Wilson(Blueprint Medicines (United States)), Michelle Maynard(Froedtert Hospital), Megan Hatlen(Blueprint Medicines (United States)), Phil Ramsden(Blueprint Medicines (United States)), Jian Guo(Yangzhou University), Rob Meissner(Blueprint Medicines (United States)), Grace Silva(Blueprint Medicines (United States)), Dean Zhang(Blueprint Medicines (United States)), Ruduan Wang(Blueprint Medicines (United States)), Emily Rozsahegyi(Blueprint Medicines (United States)), Rich Woessner(Blueprint Medicines (United States)), Tim LaBranche(Blueprint Medicines (United States)), Steve Wenglowsky(Blueprint Medicines (United States)), Neil Bifulco(Blueprint Medicines (United States)), Joseph Kim(Beth Israel Deaconess Medical Center), Victoria E. Brown(Tufts University), Yeon Sook Choi(Blueprint Medicines (United States)), Richard Vargas(Blueprint Medicines (United States)), Emanuele Perola(Blueprint Medicines (United States))
Cited by 7
Related Papers
AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic <i>IDH2</i> Mutations
|Cancer Discovery|2017|457
Precision Targeted Therapy with BLU-667 for <i>RET</i>-Driven Cancers
|Cancer Discovery|2018|397
Targeting p21-activated kinase 1 (PAK1) to induce apoptosis of tumor cells
|Proceedings of the National Academy of Sciences|2011|256
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer
|Proceedings of the National Academy of Sciences|2009|255
Postconditioning via stuttering reperfusion limits myocardial infarct size in rabbit hearts: role of ERK1/2
|American Journal of Physiology-Heart and Circulatory Physiology|2005|199